1. Introduction {#sec0005}
===============

In December 2019, a cluster of cases caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in Wuhan, Hubei Province. By April 27, 2020, more than 2.8 million cases have been reported worldwide. For such a threat to global health, the clinical characteristics, treatment strategies and its outcomes are the most concerned issues for clinicians.

People of all ages, including children, are susceptible to coronavirus disease 2019 (COVID-19). However, the sample size in the available reports on the clinical characteristics of children with COVID-19 was usually small \[[@bib0005]\]. In addition, the outcome of the treatment regimen remains to be verified in children, although a few experts' consensuses about pediatric COVID-19 have been published \[[@bib0010], [@bib0015], [@bib0020], [@bib0025]\]. Wuhan Children's Hospital is the only designated hospital for children diagnosed with COVID-19 in Hubei Province. In this study, we retrospectively analyzed the characteristics, treatment and outcome of pediatric cases in this hospital.

2. Methods {#sec0010}
==========

The observed cases were pediatric patients who were discharged from the Wuhan Children\'s Hospital from December 8, 2019 to February 29, 2020 and diagnosed with COVID-19. All cases were documented according to the oropharyngeal or anal swab samples tested positive for SARS-CoV-2 nucleic acid using RT-PCR. Confirmed patients can be discharged if their clinical symptoms improved obviously and respiratory pathogenic nucleic acid is negative for two consecutive times \[[@bib0015], [@bib0020], [@bib0025]\].

Data, included demographics, clinical, laboratory and radiological information, treatment and outcomes, were collected from patients' medical records. (1) The severity of illness was defined according to the experts' consensus \[[@bib0020]\], that is acute upper respiratory tract infection, mild pneumonia, severe pneumonia and critical cases (Supplementary Table 1). (2) The time of SARS-CoV-2 RNA clearance in respiratory samples was defined as the time from the first time of pathogenic nucleic acid positive to the test was negative without a positive test afterward. (3) Patients were diagnosed with *Mycoplasma pneumoniae* pneumonia (MPP) if they had clinical manifestations of pneumonia and / or chest radiographs suggestive of pneumonia, and the titer of IgM antibody against MP greater than 1:160.

Descriptive data were presented as number with percentages for categorical variables. Kolmogorov-Smirnov test was used to analyze whether the continuous variables were normally distributed. Medians with interquartile range (IQR) or means with standard deviations (SDs) were used for continuous variables. A Cox proportional hazards regression analysis was used to evaluate factors independently associated with length of hospital stay (LOS) or time of SARS-CoV-2 RNA clearance.

3. Results {#sec0015}
==========

A total of 75 patients have been discharged, and none have died by February 29 ([Table 1](#tbl0005){ref-type="table"} ). The mean age was 6.06 years (range 1 month-15 years). As showed in the age distribution chart ([Fig. 1](#fig0005){ref-type="fig"} ), children younger than 2 years account for the highest proportion (28.0 %) in pediatric COVID-19. A majority of the children (82.7 %) had family members diagnosed with COVID-19. With the exception of fever (53.3 %) and dry cough (61.3 %), other clinical symptoms were less common. All cases have received chest CT examination. The normal, local patchy shadowing, bilateral patchy shadowing and ground-glass opacity chest CT were observed in 22 (29.3 %), 22 (29.3 %), 26 (34.7 %) and 5 patients (6.7 %), respectively. Most children (58.7 %) did not have complications. 32.0 %, 6.7 %, and 2.7 % of patients had one, two, and three complications, respectively. The most common complication was an increase of creatine kinase-MB \[[@bib0030]\]. There was only one case with severe pneumonia and one with critical illness. Most of the children (68.0 %) have mild pneumonia, and the remaining children have acute upper respiratory infection (20.0 %) or asymptomatic infection (9.3 %). There were 42 patients co-infected with other pathogens, including mycoplasma pneumoniae (28 cases), bacteria (3 cases, including *moraxella catarrhalis*, staphylococcus aureus, streptococcus pneumoniae), influenza B virus (3 cases), influenza A virus (1 case), adenoviridae (2 cases), cytomegalovirus (1 case) and respiratory syncytial virus (1 case). But the *Mycoplasma pneumoniae* was diagosed according to antibody test which can be misleading.Table 1The characteristics of children with COVID-19.Table 1Patients (n = 75)Characteristics Age (years)6.06 ± 4.78 Height (cm)114.27 ± 37.01 Weight (kg)27.85 ± 21.99 BMI18.39 ± 4.08 Male sex44 (58.67 %)With family member diagnosed with COVID-1962 (82.67 %)Clinical symptoms Fever40 (53.33 %) Dry cough46 (61.33 %) Runny nose5 (6.67 %) Diarrhea4 (5.33 %) Sputum production4 (5.33 %) Sore throat3 (4.00 %) Fatigue3 (4.00 %) Chest Congestion3 (4.00 %) Shortness of breath2 (2.67 %) Myalgia2 (2.67 %)Chest CT No abnormality22 (29.33 %) Local patchy shadowing22 (29.33 %) Bilateral patchy shadowing26 (34.67 %) Ground-glass opacity5 (6.67 %)Severity of illness Asymptomatic infection7 (9.33 %) Acute upper respiratory tract infection15 (20.00 %) Mild pneumonia51 (68.00 %) Severe pneumonia1 (1.33 %) Critical case1 (1.33 %)Complications Increased creatine kinase-MB12 (16.00 %) Acute liver injury3 (4.00 %) Hypogammaglobulinemia2 (2.67 %) Acute kidney injury1 (1.33 %) Shock1 (1.33 %) Acute respiratory distress syndrome1 (1.33 %)Number of complications 044 (58.67 %) 124 (32.00 %) 25 (6.67 %) ≥32 (2.67 %)Comorbidities Sinus tachycardia1(1.33 %) Epilepsy as a sequel of previous viral encephalitis1(1.33 %) History of atrial septal defect surgery2 (2.67 %) Growth retardation1(1.33 %) Fatty liver disease1(1.33 %) Anaphylactoid purpura1(1.33 %)Other pathogens Mycoplasma pneumonia28 (37.33 %) Bacteria3 (4.00 %) Influenza B virus3 (4.00 %) Influenza A virus1 (1.33 %) Adenoviridae2 (2.67 %) Cytomegalovirus1 (1.33 %) Respiratory syncytial virus1 (1.33 %)Fig. 1Age distribution of the pediatric patients with COVID-19 (n = 75).Fig. 1

The treatment and clinical outcomes were showed in [Table 2](#tbl0010){ref-type="table"} . All patients received recombinant human interferon α1b nebulization (Shenzhen Kexing Biological Engineering Co., Ltd. and Beijing Sanyuan Gene Pharmaceutical Co., Ltd., China, 1−4 μg/kg/d bid). Eight cases (10.7 %) including the severe and critical patients were co-administrated with ribavirin (10 mg/kg/d bid, I.V.). Twenty-three patients (30.7 %) were given traditional Chinese medicine (TCM) for antiviral therapy, of whom 14 were mild pneumonia, and the rest were acute upper respiratory infections or asymptomatic infections. In addition, 5 cases (6.7 %) with mild pneumonia received arbidol orally (10 mg/kg/d tid for children \<50 kg; 0.6 g/d tid for children ≥50 kg) which is indicated for infection caused by influenza virus in a few countries. The mean duration from onset of symptoms to initiation of antiviral therapy was 4.91 days.Table 2The treatment and outcomes of children with COVID-19.Table 2Patients (n = 75)Treatment Interferon α1b75 (100 %) Ribavirin8 (10.67 %) Arbidol5 (6.67 %) Traditional Chinese medicine23 (30.67 %) Oseltamivir20 (26.67 %) Antibacterial agents37 (49.33 %) Azithromycin30 (40.00 %)Days from onset of symptoms to initiation of antiviral therapy4.91 ± 3.18Outcomes Days of temperature return to normal5.87 ± 4.85 Days of improvement of cough7.60 ± 4.04 Days of hospital stay10.57 ± 3.22 Days of SARS-CoV-2 clearance6.39 ± 2.29 Days of pulmonary CT improvement9.45 ± 2.52Adverse drug reaction Rash3 Diarrhea5 Hematologic toxicity1

Twenty patients (26.7 %) were administrated oseltamivir, of which 4 were positive for influenza virus nucleic acid and the rest were empirical treatment. Half of the patients have been treated with antibacterial agents (first- or second-generation cephalosporins), but most cases discontinued it after COVID-19 was confirmed. It is worth noting that 37.3 % of patients were co-infected with Mycoplasma pneumoniae, and all of them were given azithromycin orally.

The average LOS was 10.6 days ([Fig. 2](#fig0010){ref-type="fig"} ). In a multivariate Cox model analysis, we failed to observe any factor associated with LOS ([Table 3](#tbl0015){ref-type="table"} ). The mean time of SARS-CoV-2 RNA clearance was 6.4 days ([Fig. 3](#fig0015){ref-type="fig"} ). In the multivariate Cox model analysis, none of the factors was related to the time of SARS-CoV-2 RNA clearance.Fig. 2The length of hospital stay of the pediatric patients with COVID-19 (n = 75).Fig. 2Table 3Multivariate analysis of length of hospital stay and SARS-CoV-2 RNA clearance.Table 3VariableLength of hospital stayTime of SARS-CoV-2 RNA clearanceHR (95 %CI)PHR (95 %CI)PAge1.02 (0.95−1.10)0.621.03 (0.95−1.10)0.48BMI1 (0.93−1.07)0.901 (0.92−1.07)0.91Sex0.7 (0.41−1.21)0.210.77 (0.46−1.28)0.32Severity of illness0.76 (0.49−1.16)0.200.96 (0.61−1.51)0.87NO. of complications0.94 (0.72−1.24)0.680.92 (0.76−1.12)0.43Mycoplasma pneumonia2.69 (0.97−7.45)0.060.44 (0.12−1.61)0.21Bacteria0.77 (0.22−2.69)0.690.76 (0.22−2.61)0.67Virus0.43 (0.16−1.15)0.091.29 (0.50−3.29)0.60Traditional Chinese medicine0.69 (0.35−1.38)0.290.77 (0.39−1.53)0.46Arbidol1.62 (0.37−7.01)0.520.51 (0.11−2.30)0.38Ribavirin0.54 (0.18−1.61)0.271.86 (0.53−6.53)0.33Days from symptoms to antiviral therapy0.99 (0.91−1.07)0.730.98 (0.90−1.07)0.62Oseltamivir1.1 (0.53−2.31)0.801 (0.53−1.89)0.99Antibacterial agents0.86 (0.48−1.55)0.621.05 (0.58−1.88)0.88Azithromycin0.55 (0.22−1.34)0.192.26 (0.62−8.21)0.21Fig. 3The duration of SARS-CoV-2 RNA clearance in the pediatric patients with COVID-19 (n = 75).Fig. 3

4. Discussion {#sec0020}
=============

Under the current global epidemic situation, clinicians\' knowledge of the COVID-19 in children is generally lacking. We summarize the characteristics, treatment and outcomes of pediatric patients discharged from our hospital, hoping to provide a reference for diagnosis and treatment of children in other countries.

Our data suggested that infected family members were the main cause of COVID-19 in children, so healthy adults were recommended as the caregivers of children. Young children are more dependent on their family members and infants are not suitable for wearing masks, which may explain why children younger than 2 years are the most vulnerable group to COVID-19. The age distribution in our center was consistent with previous studies \[[@bib0035],[@bib0040]\]. Overall, the severity of COVID-19 in pediatric cases was milder than adults. Chinese Center for Disease Control and Prevention has analyzed the illness severity of 44,415 adult and pediatric patients, and found that severe and critical cases accounted for nearly 20 % \[[@bib0045]\]. A epidemiological study in Chinese children with COVID-19 (n = 2143) showed that severe and critical illness accounted for 5.8 % \[[@bib0050],[@bib0055]\]. In this study only 2.7 % of children were severe or critical cases. However, the severity of the disease may be underestimated because our data were calculated based on discharged patients rather than all confirmed cases, and mild cases were more likely to be discharged. The major clinical symptoms of children were similar to those of adults, such as fever and cough. But the typical symptoms (e.g. fatigue and sputum) of children were less frequent than that of adults \[[@bib0030]\]. In addition, the features of chest CT for pediatric patients were also different from adults, which has been specifically discussed by our colleagues \[[@bib0055]\].

The antiviral drugs for pediatric COVID-19 recommended in the current consensuses were summarized in Supplementary Table 2. Interferon-α nebulization and TCM were recommended for all cases, especially children with mild pneumonia. Since most of the children were relatively mild, this study was not powered to test the efficacy of these medications on outcomes.

As early as 2003, the in vitro study has found that interferon-α could effectively inhibit SARS-CoV replication \[[@bib0060]\], but its efficacy in patients remains inconclusive \[[@bib0065]\]. In our center and another three hospitals in Zhejiang Province, China, all children were given interferon-α by aerosolisation \[[@bib0045]\]. Consequently, the efficacy of interferon remains to be evaluated. In fact, interferon was commonly used in combination with ribavirin rather than alone in the treatment of SARS or Middle East respiratory syndrome (MERS) \[[@bib0070]\]. However, the efficacy of this combination in patients was still controversial \[[@bib0070],[@bib0075]\]. In our center, we have combined interferon with ribavirin for severe and critically ill patients. In the study of Qiu et al., none of the patients received ribavirin, whereas, 39 % of the patients used lopinavir-ritonavir (LPV/r) \[[@bib0045]\]. Regardless of the illness severity and other baseline characteristics, the days of hospital stay (14 ± 3 vs. 10.57 ± 3.22 days) and SARS-CoV-2 clearance (10 ± 2 vs. 6.39 ± 2.29 days) in their centers were not shorter than ours. Yet the efficacy needs to be confirmed by multi-center and large-sample research.

Several TCM treatment schedules have been proposed against COVID-19. TCM has played an important role in the treatment of adult COVID-19, especially the mild cases \[[@bib0065]\]. Xia et al. compared the clinical outcomes of combined Chinese and western medicine (34 cases) and that of western medicine (18 cases) in adult cases of COVID-19. They found that the patients who received combined Chinese and western medicine had better clinical outcomes, such as the improvement time of clinical symptom, length of hospital stay, and cure rate \[[@bib0050]\]. However, its efficiency and safety in children remain to be verified.

Arbidol is an antiviral agent indicated for upper respiratory tract infection caused by influenza virus in Russia and China. In the treatment of COVID-19, arbidol was often combined with LPV/r, and some researches showed that this combination was associated with better clinical outcomes than LPV/r alone \[[@bib0075],[@bib0080]\]. Zhu et al. compared the efficacy of arbidol monotherapy with LPV/r, and found that patients in the arbidol group had a shorter duration of positive RNA test (P \< 0.01) \[[@bib0085]\]. On February 19, arbidol was included in *National recommendations for diagnosis and treatment of respiratory infections caused by 2019-nCoV* (the 6th edition). Then we started using arbidol. So far, only 5 discharged patients have been treated with arbidol, and all of them were mild cases, so the efficacy of this drug remained to be evaluated with a larger sample.

Although limited medications were suitable for pediatric COVID-19, most children recovered within two weeks, which may be attributed to the less severity of children than adults. The outcomes of the antiviral therapy on COVID-19 need to be evaluated in a larger sample of pediatric patients.
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The following are Supplementary data to this article:

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.jcv.2020.104425>.
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